Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:6502:0:b0:439:fcfb:30e with SMTP id x2csp863717wru; Wed, 25 Mar 2026 16:49:15 -0700 (PDT) X-Received: by 2002:a05:6214:c26:b0:89a:c64:ca6 with SMTP id 6a1803df08f44-89cc4a7b72bmr87038666d6.38.1774482555002; Wed, 25 Mar 2026 16:49:15 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1774482554; cv=none; d=google.com; s=arc-20240605; b=kIf672Jlp25L0K2Z3ABuP6WovaL6k5F+Jj+Dm0pZeTEWmGoyNotNWy33LR4Cwmw60a fPSc4yLwKUKXyLks8KSZvVrMks6MIUv2hH/v4uHZNeoFMFdxVyFsAOgefSlt73/3xh45 oirFqHiHuFWY3rbk5vN13HkXI9HUg0ojkaIZLFhhwtm4xuamQu+GUZxExEivOE168gLu qtjBOo2oHWV2DV+psbPBDMX1c//NY6xvsdbO/vsuTWKzKWKyPn3dHhNPyW/4pjwtBU91 JDBBCYGiQ4NLi4S4jtE7Mhu33XjhKhlzLMXqeT+uTLIidebePzKgC4giFknbtwKfSLga nsFA== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=dLXoIN8n+ljKhq8BXa6AZwoog/nH19cAwevERIY6hiw=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=cVBCPlP/czsb+itQgAhD2UduGMyQH/IjLYLWr0hnUPkf8bSTEvYS4oIdnNmuQ1QRA2 Kr+MTAKmHLtUIsiMqhQjRoTptn2KQTh9e28KhoZZTAThDJv0i7QUTa6xUBMrkCM4uMW9 uSEDJADDHGjoKTn6EcF+OV+z3/fLOI4SPQj+2mqk+wXtjzkiztI6FQUKr0Qpxkl8CK+D EIBtJ0cYuZevaGfD8gbShGKBDgAnC+jMhdiJjDz3xbBrEEz24FysKMZVqWqavY/UhZ+Y WEyc2Zi9xVNr30cGG495ZXDZOdOvE8Ld3iM25yT5ox6paRrd90kCNsJmUzF3vwDK+O/y ncww==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=JnRJ5hHy; dkim=pass header.i=@mailgun.org header.s=mg header.b=K18oT1Ju; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.7 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v57.v5375b7fa.use4.send.mailgun.net (v57.v5375b7fa.use4.send.mailgun.net. [159.112.244.7]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-89cda955a4fsi3790176d6.223.2026.03.25.16.49.14 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Wed, 25 Mar 2026 16:49:14 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.7 as permitted sender) client-ip=159.112.244.7; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=JnRJ5hHy; dkim=pass header.i=@mailgun.org header.s=mg header.b=K18oT1Ju; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.7 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1774482554; x=1774489754; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=dLXoIN8n+ljKhq8BXa6AZwoog/nH19cAwevERIY6hiw=; b=JnRJ5hHyqPec6h6TrJsnUWGPTxJfDtja+GkE0CRpYt0tUXmZuWU//OyawjWddddg8Ljmn5Bpr/1VWvnDAH4teIDghB9QhiBDt6U8GuI1xUXKAfMAYzRYCECbgjoeJnrXDtz3400Z5CWoQuP/TqNJbz/uPbLG+gyfF8F54H1XpIA= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1774482554; x=1774489754; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=dLXoIN8n+ljKhq8BXa6AZwoog/nH19cAwevERIY6hiw=; b=K18oT1JuVVpr+FRLvokpKkcOe7eEEUr6IWQvJRhfqZkVNxh/hsp5b4tBd4DV8L98aCC0P0A5LQJsbuJGntjzWeL9vzFJ0naz9HbVEcIE7mC2b/0JCwolDAvB0GPb+QvXiDYP34OxlBbXyyA8Z95+X7J+TFJGp2uBmbyQjJtXv6E= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by eac344870724410e73893baf68098b3d7e43758b1180c4ccea284cce4fdfeb7a with HTTP id 69c4747a7e70856c89d71b02; Wed, 25 Mar 2026 23:49:14 GMT X-Mailgun-Sending-Ip: 159.112.244.7 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="7597a1fca2af388a096a9e8c035dc2d54cbe4a00bfdac486e734ad4ab88d" Subject: Breaking Down the Blend: Does GLOW or KLOW Actually Make Sense for Your Research? From: Derek from Peptide Price To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260325234907.3.9a52ca0e7795d27a@mg-d0.substack.com> Date: Wed, 25 Mar 2026 23:49:07 +0000 Feedback-Id: post-192155990:cat-post:pub-3365367:substack Sender: Derek from Peptide Price References: In-Reply-To: Reply-To: Derek from Peptide Price List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1774482554549", "is_freemail": "true", "post_audience": "everyone", "post_id": "192155990", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --7597a1fca2af388a096a9e8c035dc2d54cbe4a00bfdac486e734ad4ab88d Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/breaking-do= wn-the-blend-does-glow All compounds discussed are for research use only. Not for human consumptio= n. We=E2=80=99re kicking off a new series here =E2=80=94 breaking down all the= popular blends in the research space and giving you every angle so you can= decide whether the blend actually makes sense for your goals or whether yo= u=E2=80=99d be better off sourcing the compounds individually. No agenda ei= ther way, just the information you need to make the right call for your RS. First up: the two most popular blends in the research space right now =E2= =80=94 GLOW and KLOW. Let=E2=80=99s get into it. What=E2=80=99s in these blends? GLOW =3D GHK-Cu + BPC-157 + TB-500 KLOW =3D GHK-Cu + BPC-157 + TB-500 + KPV Typical ratios you=E2=80=99ll see: 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-= 500 / 10 mg KPV At first glance these look like powerful, all-in-one protocols. And they ar= e =E2=80=94 but =E2=80=9Call-in-one=E2=80=9D is exactly the problem. Your r= esearch goal determines which of these compounds actually belongs in your p= rotocol, and the blend locks you into fixed ratios that rarely match what y= ou need. USE CASE 1: Skin Benefits If skin optimization is the primary research goal, let=E2=80=99s talk about= what=E2=80=99s actually doing the work. GHK-Cu (Copper Peptide) =E2=80=94 the primary driver GHK-Cu is a naturally occurring tripeptide found in human plasma, saliva, a= nd urine. Its mechanisms are well-documented in the research: Stimulates collagen and elastin synthesis by upregulating TGF-=CE=B2 signal= ing Activates matrix metalloproteinases (MMPs) that break down damaged collagen= , clearing the way for new, structured collagen to replace it Promotes angiogenesis (new blood vessel formation), improving tissue oxygen= ation and nutrient delivery Has potent antioxidant effects =E2=80=94 chelates free copper ions that wou= ld otherwise generate reactive oxygen species Upregulates superoxide dismutase (SOD) and other endogenous antioxidant enz= ymes Modulates gene expression in a way that shifts skin cells toward a regenera= tive, wound-healing phenotype For the beginners: GHK-Cu essentially signals the tissue to rebuild itself.= It clears out old, damaged collagen and replaces it with fresh collagen an= d elastin. It also protects skin cells from oxidative damage. Now, BPC-157 and TB-500 do have a supporting role here. Both compounds can = accelerate collagen synthesis and tissue remodeling =E2=80=94 BPC-157 throu= gh angiogenesis and growth hormone receptor upregulation, TB-500 through ac= tin regulation and cellular migration. So there is some logic to including = them. The issue is cost. Running BPC-157 and TB-500 as part of a year-round= skin protocol is expensive, and the incremental benefit over GHK-Cu alone = likely doesn=E2=80=99t justify it for most research purposes. GHK-Cu is the= primary driver. BPC and TB-500 are a nice addition for an acute phase, not= a staple. If the RS has healthy skin with no inflammatory conditions: GHK-Cu alone is= the compound to focus on. You do not need KPV, and BPC/TB-500 are optional= additions that come with a cost tradeoff worth considering. If the RS has rosacea, eczema, psoriasis, or chronic inflammatory skin cond= itions: This is where KPV enters the picture. KPV =E2=80=94 for inflammatory skin conditions KPV is a C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte-stim= ulating hormone). Its primary mechanism is anti-inflammatory: Directly inhibits NF-=CE=BAB signaling, one of the master regulators of inf= lammatory gene expression Reduces pro-inflammatory cytokines including IL-6, IL-8, TNF-=CE=B1, and IL= -1=CE=B2 Can act locally at the site of application without significant systemic abs= orption at typical doses For the beginners: If the RS has skin that is inflamed =E2=80=94 red, react= ive, prone to flaring =E2=80=94 KPV helps quiet the inflammatory signaling = driving the condition. GHK-Cu rebuilds; KPV calms. This is exactly why the GHK-Cu + KPV blend recently came out. That pairing = makes sense for inflammatory skin research. The full GLOW or KLOW blend doe= s not, because you=E2=80=99re paying for BPC and TB-500 at ratios that don= =E2=80=99t serve this goal. USE CASE 2: Injury Recovery This is where the dosing math actively works against you. BPC-157 =E2=80=94 the healing accelerator Promotes angiogenesis at injury sites, restoring blood supply to damaged ti= ssue Upregulates growth hormone receptor expression in tendon fibroblasts, accel= erating tendon and ligament repair Modulates nitric oxide (NO) signaling, driving vasodilation and tissue perf= usion Shown to accelerate healing of muscle, tendon, ligament, bone, and gut tiss= ue in research models Typical research dosing: 500 mcg once or twice daily TB-500 (Thymosin Beta-4) =E2=80=94 the structural rebuilder Regulates actin polymerization, a fundamental process in cell movement and = tissue repair Promotes cell migration and proliferation at injury sites Reduces local inflammation in damaged tissue Works synergistically with BPC-157 =E2=80=94 BPC drives vascular regrowth, = TB-500 drives cellular migration and structural repair Typical research dosing: 500 mcg once or twice daily Here=E2=80=99s the problem with GLOW/KLOW for injury recovery To get a proper BPC-157 or TB-500 dose from a GLOW blend with a 50:10:10 ra= tio, you=E2=80=99re stuck working backwards from the BPC and TB-500 content= =2E Dosing 500 mcg of BPC and 500 mcg=20= of TB-500 once or twice daily means 1= =E2=80=932 mg of each per day =E2=80=94 but that same draw pulls along 5=E2= =80=9310 mg of GHK-Cu per day. Typical GHK-Cu research protocols land aroun= d 1=E2=80=932 mg per day. You=E2=80=99d be running 5=E2=80=9310x the intend= ed copper load just to hit your BPC and TB-500 targets. Excess free copper is not trivial. It=E2=80=99s pro-oxidant, it competes wi= th zinc for the same transport channels, and at sufficient accumulation it= =E2=80=99s documented to have toxic effects. You don=E2=80=99t want uncontr= olled copper loading as a side effect of chasing injury recovery dosing. The ratio is built for cosmetic use. It doesn=E2=80=99t translate to injury= dosing. What to run instead for injury recovery: BPC-157 + TB-500 individually =E2=80=94 full control over dosing each compo= und at the amounts the research actually supports Wolverine blend =E2=80=94 BPC + TB-500 together without GHK-Cu skewing the = ratio, designed for systemic recovery protocols Can KPV make sense for injury recovery? Yes. Its NF-=CE=BAB inhibition and = cytokine reduction can complement BPC and TB-500 by dampening the inflammat= ory environment at the injury site. But again =E2=80=94 dosing it independe= ntly gives you control the blends don=E2=80=99t. The Bottom Line Skin research (no inflammatory conditions) Run GHK-Cu as the primary compound BPC and TB-500 can support collagen remodeling acutely but are not cost-eff= ective year-round Skip KPV unless there=E2=80=99s a specific inflammatory component to addres= s Skin research (rosacea, eczema, chronic inflammation) GHK-Cu + KPV is the targeted approach =E2=80=94 the blend that just came ou= t is built for exactly this Same cost consideration applies to BPC/TB-500 for long-term use Injury recovery Run BPC-157 and TB-500 individually or as a Wolverine blend The GLOW/KLOW copper ratio will put the RS at 5=E2=80=9310x normal GHK-Cu l= evels just to hit proper BPC and TB-500 dosing KPV can be a solid add-on for inflammatory support, dosed separately Blends exist because they=E2=80=99re convenient. But you are locked into th= e vendor=E2=80=99s ratios, and for both primary use cases here, those ratio= s work against you. Buying compounds individually lets you target your actu= al research goal and control exactly what you=E2=80=99re running. Research use only. Not for human consumption. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNakUxTlRrNU1Dd2lhV0YwSWpveE56YzBOR= Gd5TlRVMExDSmxlSEFpT2pFNE1EWXdNVGcxTlRRc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LlZ5Zk9YSzhfWW9TcWU1SVNhUW1SX0NxeFJ= GbzIxWTM4X0Vqa19sTFczTkkiLCJwIjoxOTIxNTU5OTAsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc0NDgyNTU0LCJleHAiOjIwOTAwNTg1NTQsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.YiDJzmXsWRkPq-F1UjSSHMrGe-6kG0jC8NW4Cfj= 5baE? --7597a1fca2af388a096a9e8c035dc2d54cbe4a00bfdac486e734ad4ab88d Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Breaking Down the Blend:= Does GLOW or KLOW Actually Make Sense for Your Research?3D""
GLOW and KLOW aren't the blends you think they are.
͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­
=
Fo= rwarded this email? Subscribe here= for more
<= div class=3D"post-header" role=3D"region" aria-label=3D"Post header" style= =3D"font-size: 16px;line-height: 26px;">

Breaking Down the Blend: Does GLOW or KLOW Actually M= ake Sense for Your Research?

<= /tr>
Derek
 
3D""
<= table role=3D"presentation" width=3D"38" border=3D"0" cellspacing=3D"0" cel= lpadding=3D"0">
3D""=
3D""
<= /td><= /tbody>
3D""
=
READ IN APP3D""
 

All compounds discussed are f= or research use only. Not for human consumption.

We= 217;re kicking off a new series here — breaking down all the popular = blends in the research space and giving you every angle so you can decide w= hether the blend actually makes sense for your goals or whether you’d= be better off sourcing the compounds individually. No agenda either way, j= ust the information you need to make the right call for your RS.

First up: the two most popular blends in the research space right now= — GLOW and KLOW. Let’s get into it.

Upgrade to paid

What’s in these blends?

GLOW =3D GHK-Cu + BPC-157 + TB-500 KLOW =3D GHK-Cu + BPC-157 + TB-500 + KPV=

Typical ratios you’ll see: 50 m= g GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 / 10 mg KPV

=

USE CASE 1: Skin Benefits

If skin optimization is the primary research goal, let’s talk ab= out what’s actually doing the work.

GHK-Cu (C= opper Peptide) — the primary driver

GHK-Cu i= s a naturally occurring tripeptide found in human plasma, saliva, and urine= =2E Its mechanisms are well-documented= in the research:

  • Sti= mulates collagen and elastin synthesis by upregulating TGF-β signaling=

  • Activates matrix= metalloproteinases (MMPs) that break down damaged collagen, clearing the w= ay for new, structured collagen to replace it

  • Promotes angiogenesis (new blood vessel format= ion), improving tissue oxygenation and nutrient delivery

  • Has potent antioxidant effects = 212; chelates free copper ions that would otherwise generate reactive oxyge= n species

  • Upregul= ates superoxide dismutase (SOD) and other endogenous antioxidant enzymes

  • Modulates gene expr= ession in a way that shifts skin cells toward a regenerative, wound-healing= phenotype

For the beginners: GHK-Cu essentially = signals the tissue to rebuild itself. It clears out old, damaged collagen a= nd replaces it with fresh collagen and elastin. It also protects skin cells= from oxidative damage.

Now, BPC-157 and TB-500 do = have a supporting role here. Both compounds can accelerate c= ollagen synthesis and tissue remodeling — BPC-157 through angiogenesi= s and growth hormone receptor upregulation, TB-500 through actin regulation= and cellular migration. So there is some logic to including them. The issu= e is cost. Running BPC-157 and TB-500 as part of a year-round skin protocol= is expensive, and the incremental benefit over GHK-Cu alone likely doesn&#= 8217;t justify it for most research purposes. GHK-Cu is the primary driver.= BPC and TB-500 are a nice addition for an acute phase, not a staple.

If the RS has healthy skin with no inflammatory c= onditions: GHK-Cu alone is the compound to focus on. You do = not need KPV, and BPC/TB-500 are optional additions that come with a cost t= radeoff worth considering.

If the RS has ros= acea, eczema, psoriasis, or chronic inflammatory skin conditions:<= span> This is where KPV enters the picture.

KPV — for inflammatory skin conditions<= /strong>

KPV is a C-terminal tripeptide fragment of alpha-M= SH (alpha-melanocyte-stimulating hormone). Its primary mechanism is anti-in= flammatory:

  • Directly inhibits NF-κB signaling, one o= f the master regulators of inflammatory gene expression

  • Reduces pro-inflammatory cytokines= including IL-6, IL-8, TNF-α, and IL-1β

  • Can act locally at the site of application= without significant systemic absorption at typical doses

For the beginners: If the RS has skin that is inflamed — red= , reactive, prone to flaring — KPV helps quiet the inflammatory signa= ling driving the condition. GHK-Cu rebuilds; KPV calms.

This is exactly why the GHK-Cu + KPV blend= recently came out. That pairing makes sense for inflammatory skin research= =2E The full GLOW or KLOW blend does no= t, because you’re paying for BPC= and TB-500 at ratios that don’t serve this goal.

This is wher= e the dosing math actively works against you.

BPC-1= 57 — the healing accelerator

  • =

    Promotes angi= ogenesis at injury sites, restoring blood supply to damaged tissue

    • =

  • Upregulates growth hormon= e receptor expression in tendon fibroblasts, accelerating tendon and ligame= nt repair

  • Modulat= es nitric oxide (NO) signaling, driving vasodilation and tissue perfusion

  • Shown to accelerat= e healing of muscle, tendon, ligament, bone, and gut tissue in research mod= els

Typical research dosing: 500 mcg once or twice daily

TB-500 (Thymo= sin Beta-4) — the structural rebuilder

  • Reg= ulates actin polymerization, a fundamental process in cell movement and tis= sue repair

  • Promot= es cell migration and proliferation at injury sites

  • Reduces local inflammation in damaged ti= ssue

  • Works synerg= istically with BPC-157 — BPC drives vascular regrowth, TB-500 drives = cellular migration and structural repair

Ty= pical research dosing: 500 mcg once or twice daily<= /p>

Here’s the problem with GLOW/KLOW for injury = recovery

To get a proper BPC-157 or TB-500 d= ose from a GLOW blend with a 50:10:10 ratio, you’re stuck working bac= kwards from the BPC and TB-500 content. Dosing 500 mcg of BPC and 500 mcg o= f TB-500 once or twice daily means 1–2 mg of each per day — but= that same draw pulls along 5–10 mg of GHK-Cu per day<= /strong>. Typical GHK-Cu research protocols land around 1–2 mg per day. You’d be running 5–10x t= he intended copper load just to hit your BPC and TB-500 targets.

=

Excess free copper is not trivial. It’s pro-oxidant, it = competes with zinc for the same transport channels, and at sufficient accum= ulation it’s documented to have toxic effects. You don’t want u= ncontrolled copper loading as a side effect of chasing injury recovery dosi= ng.

The ratio is built for cosmetic use. It doesn&#= 8217;t translate to injury dosing.

What to= run instead for injury recovery:

  • <= p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizi= ng: border-box;padding-left: 4px;font-size: 16px;margin: 0;">BPC-15= 7 + TB-500 individually — full control over dosing eac= h compound at the amounts the research actually supports

    • Wolverine blend — BPC + TB-500 together without GHK-Cu skewing the ratio, = designed for systemic recovery protocols

<= strong>Can KPV make sense for injury recovery? Yes. Its NF-&= #954;B inhibition and cytokine reduction can complement BPC and TB-500 by d= ampening the inflammatory environment at the injury site. But again —= dosing it independently gives you control the blends don’t.

=

The Bottom Line

Skin = research (no inflammatory conditions)

  • Run GHK-Cu= as the primary compound

  • BPC and TB-500 can support collagen remodeling acutely but are not = cost-effective year-round

  • Skip KPV unless there’s a specific inflammatory component to= address

Skin research (rosacea, eczema, = chronic inflammation)

    <= li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">

    GHK-Cu + KPV is the target= ed approach — the blend that just came out is built for exactly this<= /p>

  • Same cost conside= ration applies to BPC/TB-500 for long-term use

Injury recovery

    <= li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">

    Run BPC-157 and TB-500 ind= ividually or as a Wolverine blend

  • The GLOW/KLOW copper ratio will put the RS at 5–10x = normal GHK-Cu levels just to hit proper BPC and TB-500 dosing

  • KPV can be a solid add-on for = inflammatory support, dosed separately

Blends exi= st because they’re convenient. But you are locked into the vendorR= 17;s ratios, and for both primary use cases here, those ratios work against= you. Buying compounds individually lets you target your actual research go= al and control exactly what you’re running.

Research use only. Not for human consumption.

You're currently a free subscriber to Peptide Price. For the full = experience, upgrade your subscription.

Upgrade to paid

<= td height=3D"16" style=3D"font-size:0px;line-height:0;"> 
3D""Share
 
 
<= td width=3D"8" style=3D"min-width:8px;">
= 3D""Like
3D""Comment
3D""Restack
=
 

© 2026 Derek Pruski
548 Market St= reet PMB 72296, San Francisco, CA 94104
Unsubscribe

3D"Start

3D""3D"" --7597a1fca2af388a096a9e8c035dc2d54cbe4a00bfdac486e734ad4ab88d--